JAK/TYK2

CD19 CAR T Cell Therapy in SLE (9.16.2022)

Jack Cush, MD

6 months ago

Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com First In Class, TYK2 Inhibitor FDA Approved for Psoriasis 2022 New ACR Guidance…

Dr Ai Lyn Tan DrAiLynTan

9 months 2 weeks ago

EULAR recommendations for management of #RheumatoidArthritis 6️⃣Glucocorticoids should be tapered & discontinued as soon as clinically feasible 8️⃣JAKi can be used but consider risk factors via Prof Smolen #EULAR2022 https://t.co/7cocPSpgkH

Janet Pope Janetbirdope

9 months 2 weeks ago

#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej

EULAR 2022 – Day 4 Report

Jack Cush, MD

9 months 2 weeks ago

Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…

EULAR 2022 - Day 4 Faculty Panel Recap

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Eric Dein, MD

9 months 2 weeks ago

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…

Key Psoriatic Arthritis topics and updates at EULAR 2022

Antoni Chan, MD, PhD

9 months 2 weeks ago

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA). How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as for RA…

Robert B Chao, MD doctorRBC

9 months 2 weeks ago

Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee

David Liew drdavidliew

9 months 2 weeks ago

Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change. In the 2022 version: JAKi now separate sentence following bDMARDs, with proviso to mention risk. Sometimes guidelines have to tell us what we’ve all inevitably been expecting #EULAR2022 @RheumNow https://t.co/RPbPNi3vcW

Robert B Chao, MD doctorRBC

9 months 2 weeks ago

In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7